Table 1 Clinical characteristics of the patients
From: A case series of medically managed Candida parapsilosis complex prosthetic valve endocarditis
Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
Age(years) | 55 | 71 | 70 | 64 |
Gender | Male | Male | Male | Male |
Type of surgery | Mitral valve replacement | Aortic and mitral valve replacement | Aortic valve replacement | Aortic and mitral valve replacement |
Type of valve replacement | / | Medtronic Hanko II 27# (mitral valve); Medtronic Hanko II 21# (aortic valve) | / | Edward 25# (mitral valve); Edward 21# (aortic valve) |
Possible predisposing factor for infective endocarditis | Smoking | Fungemia Hypertension Smoking | / | Hepatitis B |
Symptoms on admission | Aggravated shortness of breath for one month and edema of both lower extremities for 3 days | Fever for 20 days and shortness of breath for 3 days after activity | Repeated fever for more than 50 days and acute bloating for 12 days | Repeated fever for nearly 2 months |
Infection site | Mitral valve | Mitral valve | Aortic valve | Mitral valve |
Time post implantation | Five years | Six months | Four years | Three years |
Pathogen (isolated from blood) | Candida parapsilosis sensu stricto | Candida parapsilosis sensu stricto | Candida parapsilosis sensu stricto | Candida metapsilosis |
MIC (ug/mL) | ||||
5-Flucytosine | 4 | 4 | 4 | 4 |
Amphotericin B | 0.5 | 0.5 | 0.5 | 0.5 |
Voriconazole | 0.06 | 0.06 | 0.06 | 0.06 |
Itraconazole | 0.125 | 0.125 | 0.125 | 0.125 |
Fluconazole | 1 | 1 | 1 | 2 |
Choice ofantifungal drugs | Voriconazole, caspofungin | Voriconazole, caspofungin, amphotericin B | Voriconazole, fluconazole | Fluconazole, caspofungin |
Outcome | Successful medical therapy | Successful medical therapy | Death | Death |